Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Telix Pharmaceuticals Ltd
TLPPFCurrent price
11.66 USD
-0.22 USD (-1.84%)
Last closed
17.44 AUD
Company
telixpharma.com
ISIN
AU000000TLX2
Sector
Healthcare
Industry
Biotechnology
Exchange
AU
Capitalization
6 137 749 536 AUD
Yield for 12 month
+54.53 %
1Y
3Y
5Y
10Y
15Y
TLPPF
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia. Address: 55 Flemington Road, North Melbourne, VIC, Australia, 3051
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
37.13 AUDP/E ratio
120.2Dividend Yield
–Current Year
+505 235 512 AUD
Last Year
+162 860 604 AUD
Current Quarter
+192 226 091 AUD
Last Quarter
+286 577 735 AUD
Current Year
+313 829 339 AUD
Last Year
+29 843 604 AUD
Current Quarter
+126 020 229 AUD
Last Quarter
+227 842 692 AUD
Key Figures TLPPF
1 year
3 years
5 years
10 years
EBITDA
74 405 046 AUD
Operating Margin TTM
PE Ratio
120.2
Return On Assets TTM
7.97 %
PEG Ratio
–
Return On Equity TTM
20.49 %
Wall Street Target Price
37.13 AUD
Revenue TTM
656 826 807 AUD
Book Value
1.23 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
58.1 %
Dividend Yield
–
Gross Profit TTM
100 241 629 AUD
Earnings per share
0.15 AUD
Diluted Eps TTM
0.15 AUD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
7.62 %
Dividend Analytics TLPPF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TLPPF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation TLPPF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
120.2
Forward PE
51.8135
Enterprise Value Revenue
9.3084
Price Sales TTM
9.3445
Enterprise Value EBITDA
81.2732
Price Book MRQ
14.919
Financials TLPPF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TLPPF
For 52 weeks
8.34 AUD
21.12 AUD
50 Day MA
19.2 AUD
Shares Short Prior Month
–
200 Day MA
14.48 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart